Condition: Hematopoietic and Lymphatic System Neoplasm · Histiocytic Sarcoma · Malignant Histiocytosis · Sponsor: Mayo Clinic
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
This description comes directly from the study's public registry record.
Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Arizona | Scottsdale, Arizona, United States | Recruiting |
| Mayo Clinic in Rochester | Rochester, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06712810